Lorem Proton for liver cancer, prolonged overall survival of patients with hepatocellular carcinoma proton therapy
Hepatocellular carcinoma is the most common type of liver cancer, with more than 700,000 deaths worldwide each year, and the incidence is increasing. Treatment methods for hepatocellular carcinoma include liver transplantation, surgical resection, ablative procedures and radiotherapy (photon radiotherapy or Lorem protón). Inter illos etiam surgery est maluit curatio, sed esse posse iecoris quae translationi sunt fontes exigua redditur, multis aegris potest accipere resection iecur CIRRHOSIS et propter alias rationes.
Lorem summa salute aegri Protón poterunt
General hospitalis Massachusetts Nina Sanford, MD retrospectively quadrigis, et in medicinales effectus comparari CXXXIII de aegris cum iecur cancer exiit in opus praecipue subirent Rectum aut traditional photon Lorem protón General hospitalis apud Massachusetts inter MMVIII et MMXVII: XLIX casibus de quibus (XXXVII%)) Accipite protón Lorem. Hoc primum in Asia Lorem protón et photon radiotherapy ad carcinoma hepatocellulares.
Mediana sequi-usque studio quod tempus est XIV menses irradiatio XLV Gy dose est / XXX aut XV Gy / V ~ VI, erat LXVIII annis et media aetate in aegris. Studiis ostenditur quod altiore salvos aegris in protón Lorem coetus melius quam in photon Rectum coetus cum medianus salvos tempore XXXI mensis et XIV menses, alterum XXIV-mensis altiore salvos rates of 14% quod 45% , respectively. In eodem tempore, proton Classical Lorem potest reducere incidentiae de non-radialis-effecerunt iecoris morbus (RILD) photon Rectum comparari. XXI De aegris cum non-Classical RILD: IV et XVII accepit Lorem accepit protón photon Rectum; et curatio post III menses in Incidentia RILD dictum connectuntur cum altiore salvos. Rates loci imperium in in Proton Lorem coetus et coetus erant in photon Rectum% XCIII, et XC%, respective, et non est eadem ratio de duabus turmis regredior.
The article indicates that the longer overall survival of patients in the proton therapy group may be due to the lower incidence of decompensated liver function after treatment. Dr. Sanford said that in the United States, patients with hepatocellular carcinoma are often accompanied by other liver diseases, making these patients unable to undergo surgery and making radiotherapy more difficult. The proton therapy has a lower radiation dose to normal tissues around the tuberculum, so for patients with hepatocellular carcinoma, the non-target liver tissue receives less radiation dose. “We think this will reduce the incidence of liver injury. Because the cause of many hepatocellular carcinoma patients is other liver diseases, the lower liver injury rate in the proton therapy group can translate into better patient survival.”
COGNOSCO Predictors de iecoris injuria post Lorem protón
Rectum enim hepatocellular carcinoma adhuc controversiae quia summus dose potest facere aliis iecoris morbo quodam virium secretiori parte natium (RILD). Anderson, MD Cancer Center emissionem radiationemque oncologist Cheng En Hsieh, MD Chang Gung Memorial Hospital in Taiwan et in quadrigis identified a Predictors RILD protón post Lorem.
Non scopum iecoris volumen / volumine Ratio vexillum iecoris (ULV / SLV) volumine effectus Mearum,
Hoc studium includitur multi-centrum CXXXVI hepatocellular carcinoma in aegris tumores, qui non profecit, ut post intrahepatic protón Lorem. Et dividitur in protón Lorem in II Gye. Angiospermae procedere analysis ostendit quod non-scopum iecoris volumen / vexillum iecoris volumine Ratio (ULV / SLV), isque scopum volumine: et humilis-Pugh genere erant sui iuris Predictors de RILD et mediocris iecoris dose et scopum partus consectetuer non ad RILD Sex. In investigatores credere quod ULV / SLV pretii est maxime momenti predictor RILD; nulla potest esse causa iecoris ≥136 Gye affert. Unde ad praeventionis et curatio iecoris morbo, iecoris scopum est non-volumine plus quam mediocris in iecur dedit.
“Our data shows that if enough livers can be protected, proton therapy is safe enough and the risk of RILD can be minimized,” Dr. Hsieh said. “It’s like a liver resection, which retains enough liver The large volume of liver can be safely removed with tissue. “
Patientes estote et Selectio momenti est individuationis curatio
Marcus Dawson, MD, Praeses designatus est ASTRO, affirmavit aperiendam predictive consociata cum magno periculo factores potest auxilium iecoris injuria oncologists effluxus in statera iusta et metus utilitates ex curatio et curatio individuantur develop Insidijs.
Both studies have emphasized the need for individualized radiotherapy for liver cancer,” Dr. Dawson said. “Although there are currently suitable patient types for proton therapy, there is still insufficient clinical evidence to treat proton therapy as the liver prior to photon radiotherapy. The preferred treatment for cell cancer. We still need randomized trials (such as NRG-GI003) to guide clinical practice and make it clearer which patients can benefit from proton therapy. “
Dr. Sanford dixit: "Hoc tempore, proton Lorem adhuc in angustia rerum, et pretiosa curatio. Unde est adhuc opus ad optimize gesturum investigationis et lectio de aegris secundum protón Lorem orci vel factors Tumor biomarkers ".
